mit was administered intravenously at doses of 8 to 13 mg/m2 on day 1 for 12 malignant lymphoma patients , and 1 to 3.3 mg/m2 on day 1 through 5 for 7 acute leukemia patients and 2 malignant lymphoma patients .
C0026259
mit
C0024299
malignant lymphoma